<?xml version="1.0" encoding="UTF-8"?>
<p>In addition, DC-SIGN/CD209, a type II transmembrane adhesion molecule with C-type lectin function, is mainly expressed on interstitial dendritic cells and lung alveolar macrophages.
 <sup>
  <xref ref-type="bibr" rid="ref45">45</xref>
 </sup> DC-SIGN functions as an entry cofactor in transferring SARS-CoV to susceptible cells such as pneumocytes.
 <sup>
  <xref ref-type="bibr" rid="ref46">46</xref>
 </sup> Patent application WO200505824 claims the production of a humanized anti-DC-SIGN antibody that interfered with the interaction of DC-SIGN with its receptor, ICAM-3. The antibody effectively blocked viral binding, infection, and transmission for viral infections/diseases, including SARS.
</p>
